Company intelligence / Profile preview

ImmunGene, Inc.

Thousand Oaks, California, United Statesimmungene.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead product candidate IGN002 was in Phase 1 clinical study for relapsed/refractory non-Hodgkin lymphoma; IGN001 and IGN003 were in preclinical studies (as of 2017)

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibody-based therapiesAntibody-cytokine fusion proteinsAntibody-interferon fusion products
Industry: Biotech

Drug pipeline

1 asset

IGN002

Pre-clinical

Indications: Non-Hodgkin lymphoma

Partnerships

The Leukemia & Lymphoma SocietyValor Biotherapeutics

Beyond the preview

Go deeper on ImmunGene, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunGene, Inc..